ZUG, Switzerland, December 21 /PRNewswire/ -- AmVac AG has a new executive officer on board - Dr. Wolfgang Schmidt agreed to join the company in early December to lead its operational business.
Dr. Wolfgang Schmidt is a graduated chemist who began his career with Hoechst AG in Frankfurt/Main, Germany. After a variety of stints in pharmaceutical research, he directed the site-management Frankfurt department in the lead generation research segment. In this position he was also at the helm of the business plan competition, Science 4 Life. Next, he joined Sanofi-Aventis in Frankfurt, where he was put in charge of the management of research contracts. At AmVac, Dr. Schmidt will join forces with Mrs. Melinda-Kinga Karpati, the CEO of AmVac, to coordinate and direct the company's operational business activities as well as the integration of the new technologies acquired from the Max-Planck-Institute for Biochemistry and from the Helmholtz Center for Infection Research.
About AmVac AG
AmVac AG is a company engaged in the biological/pharmaceutical market headquartered in Switzerland, and focuses on the market for inoculation supplies.
This press release constitutes neither an offer to sell nor a solicitation to buy securities of AmVac AG in any jurisdiction. This press release must not be issued in the United States of America and must not be distributed to United States persons or publications with a general circulation in the United States.
Contact AmVac AG Ariane Meynert Metallstrasse 4 CH-6300 Zug Tel.: +41-41-725-32-34 Fax: +41-41-725-32-39 Mobile: +41-79-793-34-19 Mobile: +49-1-727-75-92-12 Email: email@example.com
Contact: AmVac AG, Ariane Meynert, Metallstrasse 4, CH-6300 Zug, Tel.: +41-41-725-32-34, Fax: +41-41-725-32-39, Mobile: +41-79-793-34-19, Mobile: +49-1-727-75-92-12, Email: firstname.lastname@example.org